Physician profile
Morgan Flaherty
NPI 1245205517
$9,050.85
in general payments reported to CMS, 2019-2025
34 companies · $170 in 2025
The $170 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,790 · 2020: $1,039 · 2021: $1,870 · 2022: $956 · 2023: $226 · 2025: $170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $396.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $395.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,001.65 | 2019-2021 | |
| Abbvie INC. | $791.66 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $688.26 | 2019-2022 | |
| Amgen INC. | $625.50 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $467.88 | 2019-2022 | |
| Avanir Pharmaceuticals, INC. | $458.52 | 2019 | |
| Grifols USA, LLC | $412.69 | 2019-2025 | Prolastin-C Liquid, Xembify |
| Amarin Pharma, INC. | $349.80 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $279.05 | 2019-2021 | |
| Emd Serono, INC. | $272.82 | 2019-2021 | |
| Lilly USA, LLC | $271.91 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $262.34 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $249.98 | 2021 | |
| Biogen, INC. | $242.94 | 2021-2022 | |
| Mdd US Operations, LLC | $236.85 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $235.82 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $229.16 | 2019 | |
| Radius Health, INC. | $226.88 | 2019 | |
| Allergan, INC. | $197.63 | 2020 | |
| Mallinckrodt Hospital Products INC. | $186.06 | 2022 | |
| Novo Nordisk INC | $180.30 | 2019 | |
| Acorda Therapeutics, INC | $180.28 | 2019 | |
| Horizon Therapeutics Plc | $124.99 | 2019 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $124.99 | 2022 | |
| Sk Life Science, INC. | $119.58 | 2021 | |
| Shire North American Group INC | $107.13 | 2019 | |
| Amneal Pharmaceuticals LLC | $105.89 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $99.12 | 2019 | |
| Neurocrine Biosciences, INC. | $95.18 | 2023 | Ingrezza |
| Ucb, INC. | $85.78 | 2019 | |
| Csl Behring | $68.18 | 2020 | |
| Genentech USA, INC. | $31.66 | 2019 | |
| Glaxosmithkline, LLC. | $22.44 | 2021 | |
| Pfizer INC. | $17.93 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morgan Flaherty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.